Mobilizing Oxygen, Transforming Lives.
A First-in-Class Oxygen Therapeutic
Our mission is to reverse tissue hypoxia. Hypoxia occurs when the body's cells don't get enough oxygen, this plays a significant role in various fatal diseases. We are committed to patient safety and ensuring their access to life-saving oxygen therapeutics.
Clinical Programs
NuvOx Therapeutics is a clinical stage pharmaceutical company developing a drug that aims to improve the flow of oxygen from lungs to blood and from blood to tissue. Over 30 animal studies have shown therapeutic effect in seven different indications. Phase Ib/IIa clinical trials in stroke and oncology generated compelling results. The Company is currently enrolling 87 glioblastoma subjects in a prospective, randomized, placebo controlled Phase IIb clinical trial as a radio sensitizer. All glioblastoma patients receive standard chemoradiation treatment. The Company has received grant funding from National Institute of Neurological Disorders and Stroke (NINDS) to support evaluation of NanOâ‚‚ as a neuroprotectant by the Stroke Preclinical Assessment Network (SPAN). The National Institute of Health and Care Research (NIHR) in the UK is supporting a Phase IIb clinical trial of NanOâ‚‚ in large vessel occlusion stroke. The trial will treat approximately 150 stroke subjects and is expected to begin in 2025 and is sponsored by our UK collaborators. In addition, the Company is launching a Phase Ib clinical trial for respiratory distress, which is also expected to start in 2025. This trial is partially sponsored by US Department of Health & Human Services, Biomedical Advanced Research and Development Authority (BARDA).
NanOâ‚‚ is under clinical investigation and not yet approved for general medical use.
Clinical Pipeline
NanOâ‚‚
